Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoine Thiery-Vuillemin

Showing results (1-10 of 112) with videos related to

Pageof 12
Sort By:
Bulletin Du Cancer|July 5, 2020
[Updates in onco-urology: academic research is a key factor]Antoine Thiery-Vuillemin
Bulletin Du Cancer|June 27, 2022
Emergence of new strategies in metastatic kidney cancer: Emergence des nouvelles stratégies dans le cancer du rein métastatiqueAntoine Thiery-Vuillemin
Bulletin Du Cancer|October 20, 2018
[Cytoreduction nephrectomy: No future?]Loic Balssa, François Kleinclauss, Hamadi Almotlak, et al.
Bulletin Du Cancer|May 22, 2021
FGFR alterations in urothelial carcinoma: Picking the right targetPaul Hubert, Zohair Selmani, Yohann Loriot, et al.
The French Journal of Urology|December 5, 2024
High-risk non-muscle invasive bladder cancer: Outcomes of patients who cannot benefit from standard of careThomas Palkowski, Frédéric Bibeau, Antoine Thiery-Vuillemin, et al.
Bulletin Du Cancer|January 1, 2019
Benoîte Mery, Antoine Thiery-Vuillemin, Christophe Massard, et al.
Bulletin Du Cancer|July 1, 2024
[Onco-nephrology: Origins, organization and perspectives]Matthieu Delaye, Jacques-Olivier Bay, Antoine Thiery-Vuillemin, et al.
Anti-Cancer Drugs|April 7, 2011
Combining molecular targeted therapies: clinical experienceXavier Pivot, Nadia Bedairia, Antoine Thiery-Vuillemin, et al.
Bulletin Du Cancer|June 18, 2022
Adjuvant therapy in renal cell carcinoma: Ready, steady, should we go?Claire Antoun, Loic Choffel, Alexandre Frontczak, et al.
Clinical Genitourinary Cancer|September 1, 2022
Management and Health Resource Use of Patients With Metastatic Renal Cell Carcinoma treated With Systemic Therapy Over 2014-2017 in France: A National Real-World StudyBernard Escudier, Marie de Zélicourt, Redha Bourouina, et al.
Pageof 12

Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
Bulletin Du Cancer|July 5, 2020
[Updates in onco-urology: academic research is a key factor]Antoine Thiery-Vuillemin
Bulletin Du Cancer|June 27, 2022
Emergence of new strategies in metastatic kidney cancer: Emergence des nouvelles stratégies dans le cancer du rein métastatiqueAntoine Thiery-Vuillemin
Bulletin Du Cancer|October 20, 2018
[Cytoreduction nephrectomy: No future?]Loic Balssa, François Kleinclauss, Hamadi Almotlak, et al.
Bulletin Du Cancer|May 22, 2021
FGFR alterations in urothelial carcinoma: Picking the right targetPaul Hubert, Zohair Selmani, Yohann Loriot, et al.
The French Journal of Urology|December 5, 2024
High-risk non-muscle invasive bladder cancer: Outcomes of patients who cannot benefit from standard of careThomas Palkowski, Frédéric Bibeau, Antoine Thiery-Vuillemin, et al.
Bulletin Du Cancer|January 1, 2019
Benoîte Mery, Antoine Thiery-Vuillemin, Christophe Massard, et al.
Bulletin Du Cancer|July 1, 2024
[Onco-nephrology: Origins, organization and perspectives]Matthieu Delaye, Jacques-Olivier Bay, Antoine Thiery-Vuillemin, et al.
Anti-Cancer Drugs|April 7, 2011
Combining molecular targeted therapies: clinical experienceXavier Pivot, Nadia Bedairia, Antoine Thiery-Vuillemin, et al.
Bulletin Du Cancer|June 18, 2022
Adjuvant therapy in renal cell carcinoma: Ready, steady, should we go?Claire Antoun, Loic Choffel, Alexandre Frontczak, et al.
Clinical Genitourinary Cancer|September 1, 2022
Management and Health Resource Use of Patients With Metastatic Renal Cell Carcinoma treated With Systemic Therapy Over 2014-2017 in France: A National Real-World StudyBernard Escudier, Marie de Zélicourt, Redha Bourouina, et al.
Pageof 12